Hizentra (Human Normal Immunoglobulin)

Hizentra is used as an immunoglobulin replacement therapy for individuals whose immune systems cannot produce adequate antibodies.

• Primary immunodeficiency diseases such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia.
• Secondary immunodeficiency conditions resulting from chemotherapy, hematopoietic stem cell transplantation, or HIV infection.
• Maintenance therapy to reduce the frequency and severity of infections in antibody‑deficient patients.
• Adjunctive treatment for patients requiring regular IgG supplementation when intravenous administration is not feasible.

• Human normal immunoglobulin in Hizentra consists primarily of IgG antibodies that circulate in the bloodstream. After subcutaneous administration, the IgG is absorbed into the systemic circulation, where it binds to a broad range of antigens and neutralizes pathogens. By supplementing deficient endogenous IgG, the product restores humoral immunity, enhances opsonization, and supports complement activation, thereby providing passive protection against bacterial and viral infections.

Adverse reactions to Hizentra may occur following subcutaneous administration.

Common

• Injection site reactions such as redness, swelling, or itching.
• Headache.
• Fatigue or malaise.
• Nausea or mild gastrointestinal discomfort.

Serious

• Severe allergic reactions including anaphylaxis or angioedema.
• Thromboembolic events such as deep vein thrombosis.
• Renal impairment or hemolysis.
• Aseptic meningitis.

Before using Hizentra, patients and clinicians should consider several safety precautions.

• Assess for known hypersensitivity to immunoglobulin products or any component of the formulation.
• Monitor for signs of infection or worsening immune deficiency during therapy.
• Use caution in individuals with a history of thromboembolic disease or cardiovascular risk factors.
• Evaluate renal function periodically, especially in patients with pre‑existing kidney disease.
• Adjust dosing or discontinue if severe infusion‑related reactions occur.
• Consider pregnancy and lactation status; data are limited, and benefits should outweigh potential risks.

Hizentra may interact with other medications or medical conditions; certain combinations should be avoided or used carefully.

Avoid

• Concurrent use of other immunoglobulin products, which can increase the risk of hyperviscosity.
• Live vaccines, because passive antibodies may reduce vaccine efficacy and increase adverse events.

Use with caution

• Anticoagulants or antiplatelet agents, as subcutaneous IgG can affect coagulation parameters.
• Diuretics, due to potential fluid shifts and renal considerations.
• ACE inhibitors or ARBs, because of possible additive effects on blood pressure.
• Immunosuppressive therapies, which may alter the clinical response to IgG replacement.